DZ 002
Alternative Names: DZ-002Latest Information Update: 03 Oct 2025
At a glance
- Originator Da Zen Theranostics
- Class Antineoplastics; Drug conjugates
- Mechanism of Action Undefined mechanism
- 
          
            
              Orphan Drug Status
              NoOrphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. 
- New Molecular Entity Yes
Highest Development Phases
- Phase I Lymphoma; Solid tumours
Most Recent Events
- 03 Oct 2025 DZ 002 is still in phase I trials for Solid tumours and Lymphoma (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT04970992)
- 28 Sep 2024 No recent reports of development identified for phase-I development in Lymphoma(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Injection)
- 28 Sep 2024 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Injection)
